文献速递妇科

程序性细胞死亡受体1及其配体在卵巢上皮性癌标本中的表达及意义

[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2020-01-01

回顾性分析180例卵巢上皮性癌组织标本及50例癌旁正常卵巢组织,采用免疫组化SP法检测PD-1与PD-L1表达。癌组织两者阳性表达率均为18.3%(33/180),显著高于癌旁的2.0%(1/50)(P<0.01)。PD-1或PD-L1阳性患者中位生存时间分别为35和36个月,均短于阴性者的61个月(P<0.05)。

要点

  • 卵巢癌组织PD-1及PD-L1阳性表达率均为18.3%(33/180),癌旁正常组织为2.0%(1/50)(P<0.01)。
  • PD-1及PD-L1阳性表达与晚期、Ⅱ型、双侧累及及浆液性癌相关(P<0.05)。
  • PD-1阳性者中位生存35个月、PD-L1阳性者36个月,均短于阴性者61个月(P<0.05)。

核心结论

  • 卵巢癌组织中PD-1及PD-L1表达均高于癌旁正常卵巢组织,以浆液性癌较为明显。
  • 晚期卵巢癌患者PD-1及PD-L1表达较高,两者阳性表达是卵巢癌患者预后不良的指标。

研究设计与样本

  • 选取2002年10月至2013年12月大连医科大学附属第一医院经手术治疗且病理证实的卵巢癌组织标本180份,包括浆液性癌120份、黏液性癌30份、子宫内膜样癌15份、透明细胞癌15份。
  • 从180例中随机选取50份癌旁正常卵巢组织标本作为对照。
  • 采用免疫组化SP法检测PD-1及PD-L1表达,并分析其与临床病理特征及预后之间的关系。

主要发现

  • PD-1表达于癌组织内浸润的淋巴细胞,PD-L1表达于癌细胞细胞膜;癌旁正常卵巢组织中PD-1及PD-L1均呈阴性表达。
  • 卵巢癌组织PD-1及PD-L1阳性表达率均为18.3%(33/180),癌旁正常组织为2.0%(1/50),两组比较差异有统计学意义(P<0.01)。
  • 浆液性癌PD-1阳性表达率为25.0%(30/120),子宫内膜样癌为3/15,黏液性癌为0(0/30),透明细胞癌为0(0/15)。
  • 浆液性癌PD-L1阳性表达率为23.3%(28/120),黏液性癌为3.3%(1/30),子宫内膜样癌为2/15,透明细胞癌为2/15,四种亚型间差异有统计学意义(P<0.05)。
  • PD-1及PD-L1均高表达率早期(Ⅰ、Ⅱ期)为9.2%(8/87),晚期(Ⅲ、Ⅳ期)为26.9%(25/93),两组比较差异有统计学意义(P<0.01);Ⅱ型高于Ⅰ型、双侧卵巢累及者高于单侧者,差异均有统计学意义(P<0.05)。

关键数值与推荐

  • PD-1阳性与阴性表达患者中位生存时间分别为35个月与61个月,差异有统计学意义(P<0.05)。
  • PD-L1阳性与阴性表达患者中位生存时间分别为36个月与61个月,差异有统计学意义(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To examine the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in epithelial ovarian cancer (EOC) tissues, and investigate the correlation among their expression, clinicopathological features and prognosis. Methods: The specimens of 180 patients with EOC treated in the First Affiliated Hospital of Dalian Medical University from October 2002 to December 2013 were confirmed by pathological examination. The pathological tissue specimens of subtypes ,included 120 cases of serous carcinoma, 30 cases of mucinous carcinoma, 20 cases of endometrioid carcinoma, and 20 cases of clear cell carcinoma. The normal paracancerous tissues of 50 cases randomly selected from the 180 patients as control group. Immunohistochemical SP method was used to detect the expressions of both PD-1 and PD-L1 in epithelial ovarian cancer tissues, and the relationships among their expressions,the clinicopathological parameters and prognosis were respectively analyzed. Results: (1) PD-1 was expressed in lymphocytes infiltrated in EOC tissues, and PD-L1 was expressed in the cell membranes of cancer tissues. In all EOC cases, 33 cases (18.3%, 33/180) of both PD-1 and PD-L1 were highly expressed, and only 1 (2.0%, 1/50) of control group showed high expression. There was statistically significant difference between two groups (P<0.01). (2) Among the four subtypes tissue specimens of EOC, the high expression rate of PD-1 was 25.0% (30/120) for serous carcinoma, 3/15 for endometrioid carcinoma, 0 (0/30) for mucinous carcinoma, and 0 (0/15) for clear cell carcinoma. The high expression rate of PD-L1 was 23.3% (28/120) for serous carcinoma, 3.3% (1/30) for mucinous carcinoma, 2/15 for endometrioid carcinoma, and 2/15 for clear cell carcinoma. Both PD-1 and PD-L1 expressions in the four sub-types of tissue specimens were significantly different (P<0.05). The high expression rate of both PD-1 and PD-L1 was 9.2% (8/87) in the early stage and 26.9% (25/93) in the late stage. There was a statistically significant difference between the two groups (P<0.01). Similarly, the expression of both PD-1 and PD-L1 were significantly higher in the cases of high-grade EOC (type Ⅱ) than those of low-grade (type Ⅰ) and in the cases of EOC distributed bilaterally than that distributed unilaterally, and there were statistically significant differences (P<0.05). (3) The Kaplan-Meier survival analysis showed that the survival time were respectively 35 and 36 months in the cases with high expressions of both PD-1 and PD-L1, and the survival time were the same as 61 months in the cases with low expression of both PD-1 and PD-L1, and the comparison was statistically significant (P<0.05). Conclusions: The expression levels of PD-1 and PD-L1 in EOC tissues are higher than those in adjacent tissues, especially in serous carcinomas. The expression of both PD-1 and PD-L1 is higher in specimens of the patients with advanced stages. The results showed that the high expression of both PD-1 and PD-L1 is an indicator of poor prognosis of patients suffering from EOC. 目的: 探讨程序性细胞死亡受体1(PD-1)及其配体(PD-L1)在卵巢上皮性癌(卵巢癌)组织中的表达及其意义。 方法: 选取2002年10月—2013年12月大连医科大学附属第一医院经手术治疗且经病理检查证实为卵巢癌的组织标本180份,包括浆液性癌120份,黏液性癌30份,子宫内膜样癌15份,透明细胞癌15份;从中随机选取50份癌旁的正常卵巢组织标本作为对照。采用免疫组化SP法检测卵巢癌和正常卵巢组织中PD-1及PD-L1的表达,并分析PD-1及PD-L1的表达与卵巢癌患者不同临床病理特征及预后之间的关系。 结果: (1)卵巢癌和正常卵巢组织中PD-1及PD-L1的表达:PD-1表达于癌组织内浸润的淋巴细胞中,PD-L1表达于癌细胞的细胞膜;在癌旁的正常卵巢组织中PD-1及PD-L1均呈阴性表达。卵巢癌、正常卵巢组织中PD-1及PD-L1的阳性表达率分别均为18.3%(33/180)、2.0%(1/50),两者比较,差异有统计学意义(P<0.01)。(2)不同临床病理特征的卵巢癌组织中PD-1及PD-L1的表达:卵巢癌组织中PD-1、PD-L1的阳性表达率,浆液性癌均高于非浆液性癌(包括黏液性癌、子宫内模样癌、透明细胞癌),手术病理分期为Ⅲ、Ⅳ期者高于Ⅰ、Ⅱ期,发病模式为Ⅱ型者高于Ⅰ型,肿瘤累及侧别为双侧卵巢者高于单侧卵巢者,分别比较,差异均有统计学意义(P<0.05)。(3)不同PD-1、PD-L1表达的卵巢癌患者的生存情况:PD-1阳性、阴性表达患者的中位生存时间分别为35、61个月,PD-L1阳性、阴性表达患者的中位生存时间分别为36、61个月,两者分别比较,差异均有统计学意义(P<0.05)。 结论: PD-1及PD-L1在卵巢癌组织中的表达均高于癌旁的正常卵巢组织,特别是浆液性癌较为明显;晚期卵巢癌患者PD-1及PD-L1的表达较高,表明PD-1及PD-L1阳性表达是卵巢癌患者预后不良的指标。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ju C, Gao JC, Zhang PX, et al. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2020. PMID: 32854477. doi:10.3760/cma.j.cn112141-20200301-00155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。